Table 2.
Immunologic investigations assessing immune function and causes of immune deficiency
| Patient A | Patient B | Patient C | Patient D | Patient E | Normal range7, 8, 9 | |
|---|---|---|---|---|---|---|
| Investigations at ALL diagnosis | ||||||
| ALC (cells/μl) | 14,600 | 12,700 | 0 | n/a | n/a | 3,400–9,000 |
| IgG (g/l) | 5.61 | 2.15 | 8.27 | n/a | n/a | 2.4–8.8 |
| Abnormal viral serology | CMV IgM positive, CMV IgG positive | EBV IgG positive | CMV PCR positive | n/a | None | |
| Investigations after completion of chemotherapy treatment | ||||||
| Time since completion of chemotherapy treatment | 2 months | 2 months | 13 months | 3 months | 7 months | |
| ANC (cells/μl) | 2,389 | 2,400 | 882 | 21,597 | 4,290 | 2,000–7,100 |
| ALC (cells/μl) | 210 | 1,400 | 82 | n/a | 1,670 | 2,300–5,400 |
| CD3+ (cells/μl) | 82 (39%a) | 14 (1%) | 25 (38%) | n/a (1.7%) | <17 (<1%) | 1,400–3,700 (56–75%) |
| CD4+ (cells/μl) | 4 (2%) | 14 (1%) | <20 (<1%) | n/a (0.5%) | <17 (<1%) | 700–2,200 (28–47%) |
| CD8+ (cells/μl) | 67 (32%) | 0 (0%) | 23 (35%) | n/a (0.7%) | <17 (<1%) | 490–1,300 (16–30%) |
| CD19+ (cells/μl) | 23 (11% ) | 1,065 (74%) | <20 (<1%) | n/a (1.6%) | 1,486 (89.9%) | 390–1,400 (14–33%) |
| CD56+ (cells/μl) | 84 (40% ) | 187 (13%) | 41 (62%) | n/a (93.7%) | 167 (10.1%) | 130–720 (4–17%) |
| IgG (g/l) | 4.91 | 2.07 | 2.89 | 2.13 | <0.33 | 7.1–11.6 |
| Other | TRECs normal | RAG2 gene normal | TRECs normal | None | IL7RA, JAK3, DCLRE1C, ADA genes and PNP activity, all normal | |
ALL, acute lymphoblastic leukemia; ALC, absolute lymphocyte count; IgG, immunoglobulin G; CMV, cytomegalovirus; EBV, Epstein‐Barr Virus; PCR, polymerase change reaction; IgM, immunoglobulin M; TREC, T‐cell receptor excision circles; RAG2, IL7RA, JAK3, DCLRE1C, and ADA are common mutations that cause severe combined immunodeficiency; PNP, purine nucleoside phosphorylase deficiency; n/a, information not available.
Percentage of absolute lymphocyte count.
This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.